Get Live Data

Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada
Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in CanadaView Video
Roundtable Discussion; The Future of Mineral Sands
Roundtable Discussion; The Future of Mineral SandsView Video

Latest Share Chat

  2. Share Prices
  3. Glaxosmithkline Share Price
  4. Glaxosmithkline Share News
  5. BROKER RATINGS SUMMARY: Deutsche Bank Starts Taylor Wimpey At Buy

Pin to quick picksGlaxosmithkline Share News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,705.00
Bid: 1,701.00
Ask: 1,701.50
Change: 32.00 (1.91%)
Spread: 0.50 (0.029%)
Open: 1,685.50
High: 1,718.50
Low: 1,673.00
Prev. Close: 1,673.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Deutsche Bank Starts Taylor Wimpey At Buy

Tue, 03rd Sep 2019 09:40

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

----------

FTSE 100

----------

DEUTSCHE BANK INITIATES TAYLOR WIMPEY WITH 'BUY' - TARGET 187 PENCE

----------

DEUTSCHE BANK RESUMES BARRATT DEVELOPMENTS WITH 'HOLD' - TARGET 648 PENCE

----------

DEUTSCHE BANK RESUMES BERKELEY GROUP WITH 'SELL' - TARGET 3428 PENCE

----------

DEUTSCHE BANK RESUMES PERSIMMON WITH 'BUY' - TARGET 2386 PENCE

----------

BARCLAYS RAISES RSA INSURANCE PRICE TARGET TO 603 (600) PENCE - 'OVERWEIGHT'

----------

BARCLAYS RAISES PRUDENTIAL PRICE TARGET TO 2088 (2069) PENCE - 'OVERWEIGHT'

----------

BARCLAYS CUTS PHOENIX GROUP PRICE TARGET TO 657 (664) PENCE - 'EQUAL WEIGHT'

----------

BARCLAYS RAISES LEGAL & GENERAL PRICE TARGET TO 331 (320) PENCE - 'OVERWEIGHT'

----------

BARCLAYS RAISES HISCOX PRICE TARGET TO 1556 (1514) PENCE - 'UNDERWEIGHT'

----------

BARCLAYS CUTS DIRECT LINE PRICE TARGET TO 347 (354) PENCE - 'EQUAL WEIGHT'

----------

BARCLAYS RAISES AVIVA PRICE TARGET TO 551 (550) PENCE - 'OVERWEIGHT'

----------

BARCLAYS CUTS ADMIRAL GROUP PRICE TARGET TO 2288 (2314) PENCE - 'OVERWEIGHT'

----------

CITIGROUP REINITIATES GLAXOSMITHKLINE WITH 'NEUTRAL' - PRICE TARGET 1840 PENCE

----------

UBS CUTS WM MORRISON SUPERMARKETS PRICE TARGET TO 245 (260) PENCE - 'BUY'

----------

UBS CUTS MICRO FOCUS PRICE TARGET TO 1530 (2050) PENCE - 'BUY'

----------

FTSE 250

----------

BOFA CUTS ASHMORE GROUP TO 'NEUTRAL' ('BUY')

----------

UBS CUTS PAGEGROUP PRICE TARGET TO 440 (495) PENCE - 'NEUTRAL'

----------

UBS CUTS HAYS PRICE TARGET TO 140 (165) PENCE - 'NEUTRAL'

----------

DEUTSCHE BANK RESUMES BELLWAY WITH 'BUY' - TARGET 3538 PENCE

----------

DEUTSCHE BANK RESUMES BOVIS HOMES WITH 'HOLD' - TARGET 1085 PENCE

----------

DEUTSCHE BANK RESUMES MCCARTHY & STONE WITH 'HOLD' - TARGET 137 PENCE

----------

DEUTSCHE BANK RESUMES COUNTRYSIDE PROPERTIES WITH 'BUY' - TARGET 353 PENCE

----------

DEUTSCHE BANK RESUMES REDROW WITH 'BUY' - TARGET 728 PENCE

----------

KEPLER CHEUVREUX CUTS EASYJET TO 'REDUCE' (HOLD) - PRICE TARGET 820 (1200) PENCE

----------

BARCLAYS CUTS LANCASHIRE HOLDINGS PRICE TARGET TO 727 (731) PENCE - 'EQUAL WEIGHT'

----------

BARCLAYS RAISES HASTINGS GROUP PRICE TARGET TO 225 (220) PENCE - 'OVERWEIGHT'

----------

GOLDMAN SACHS RAISES GVC HOLDING PRICE TARGET TO 1000 (950) PENCE - 'BUY'

----------

OTHER MAIN MARKET AND AIM

----------

LIBERUM RAISES AB DYNAMICS PRICE TARGET TO 3085 (2750) PENCE - 'BUY'

----------

More News
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
21 Nov 2023 11:52

GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024

(Alliance News) - GSK PLC on Tuesday said it will begin phase 3 trials of a low carbon version of its metered dose inhaler Ventolin using a "next generation" propellant in 2024.

Read more
5678910111213

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.